Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc., as indicated in the metadata) on June 12, 2017. The filing reports the closing of a registered direct offering of common stock and warrants.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance. Key metrics include:
- Gross Proceeds: $10.0 million.
- Shares Sold: 3,030,304 shares of common stock.
- Warrants Issued: Warrants to purchase 1,515,152 shares of common stock.
- Offering Price: $3.30 per unit (one share plus one warrant).
- Warrant Exercise Price: $4.00 per share.
- Placement Agent Warrants: 181,818 shares at an exercise price of $4.125 per share.
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new shares and warrants. This event was previously disclosed in a Form 8-K filed on June 7, 2017.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the offering terms. The proceeds are intended to fund the company's operations, though specific allocation is not detailed in this excerpt.
Investor Verification Checklist
- Verify the total number of outstanding shares post-offering to assess dilution impact.
- Confirm the use of proceeds as outlined in the June 7, 2017, preliminary filing.
- Review the warrant terms (exercise price of $4.00 and $4.125) relative to the current market price.
- Check for any subsequent filings regarding the placement agent warrants.